Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/301% above fair value
$69.00−0.84 (-1.20%)
Close on Nov 13, 2026Market cap $16.84BP/E 20.7Yield –
Exelixis ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Exelixis's ebitda for the twelve months ending Oct 2, 2026 was $1.03B, up 24.3% year over year. For fiscal 2025 it was $901.25M, up 42.3% from the year before. The highest annual figure on record is $901.25M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $901.25M | +42.3% |
| FY2024 | Jan 3, 2025 | $633.42M | +222.2% |
| FY2023 | Dec 29, 2023 | $196.60M | -11.6% |
| FY2022 | Dec 30, 2022 | $222.36M | -26.0% |
| FY2021 | Dec 31, 2021 | $300.30M | +151.9% |
| FY2020 | Jan 1, 2021 | $119.20M | -68.5% |
| FY2019 | Jan 3, 2020 | $377.82M | -14.9% |
| FY2018 | Dec 28, 2018 | $443.77M | +165.6% |
| FY2017 | Dec 29, 2017 | $167.10M | – |
| FY2016 | Dec 31, 2016 | -$27.12M | – |
| FY2015 | Dec 31, 2015 | -$120.02M | – |
| FY2014 | Dec 31, 2014 | -$222.07M | – |
| FY2013 | Dec 31, 2013 | -$197.59M | – |
| FY2012 | Dec 31, 2012 | -$116.92M | -221.3% |
| FY2011 | Dec 31, 2011 | $96.36M | – |
| FY2010 | Dec 31, 2010 | -$80.85M | – |
| FY2009 | Dec 31, 2009 | -$109.31M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | $275.36M | +12.9% |
| Q2 FY2026 | Jul 3, 2026 | $255.40M | +15.6% |
| Q1 FY2026 | Apr 3, 2026 | $258.29M | +33.0% |
| Q4 FY2025 | Jan 2, 2026 | $242.16M | +41.7% |
| Q3 FY2025 | Oct 3, 2025 | $243.96M | +70.0% |
| Q2 FY2025 | Jul 4, 2025 | $220.92M | -22.0% |
| Q1 FY2025 | Apr 4, 2025 | $194.20M | +441.9% |
| Q4 FY2024 | Jan 3, 2025 | $170.85M | +93.5% |
| Q3 FY2024 | Sep 27, 2024 | $143.53M | – |
| Q2 FY2024 | Jun 28, 2024 | $283.20M | +237.6% |
| Q1 FY2024 | Mar 29, 2024 | $35.84M | +0.4% |
| Q4 FY2023 | Dec 29, 2023 | $88.31M | – |
| Q3 FY2023 | Sep 29, 2023 | -$11.29M | -112.8% |
| Q2 FY2023 | Jun 30, 2023 | $83.89M | -5.2% |
| Q1 FY2023 | Mar 31, 2023 | $35.69M | -59.3% |
| Q4 FY2022 | Dec 30, 2022 | -$42.13M | -135.5% |
| Q3 FY2022 | Sep 30, 2022 | $88.28M | +56.4% |
| Q2 FY2022 | Jul 1, 2022 | $88.48M | -30.2% |
| Q1 FY2022 | Apr 1, 2022 | $87.73M | – |
| Q4 FY2021 | Dec 31, 2021 | $118.58M | +344.0% |
| Q3 FY2021 | Oct 1, 2021 | $56.43M | – |
| Q2 FY2021 | Jul 2, 2021 | $126.68M | +63.0% |
| Q1 FY2021 | Apr 2, 2021 | -$1.38M | -102.5% |
| Q4 FY2020 | Jan 1, 2021 | $26.71M | -66.4% |
| Q3 FY2020 | Oct 2, 2020 | -$40.23M | -134.2% |
| Q2 FY2020 | Jul 3, 2020 | $77.74M | -17.3% |
| Q1 FY2020 | Apr 3, 2020 | $54.98M | -36.5% |
| Q4 FY2019 | Jan 3, 2020 | $79.58M | -30.0% |
| Q3 FY2019 | Sep 27, 2019 | $117.70M | -7.2% |
| Q2 FY2019 | Jun 28, 2019 | $94.03M | +8.6% |
| Q1 FY2019 | Mar 29, 2019 | $86.52M | -25.8% |
| Q4 FY2018 | Dec 28, 2018 | $113.64M | +200.8% |
| Q3 FY2018 | Sep 28, 2018 | $126.88M | +55.8% |
| Q2 FY2018 | Jun 29, 2018 | $86.58M | +216.0% |
| Q1 FY2018 | Mar 30, 2018 | $116.68M | +470.1% |
| Q4 FY2017 | Dec 29, 2017 | $37.78M | -3.5% |
| Q3 FY2017 | Sep 30, 2017 | $81.46M | – |
| Q2 FY2017 | Jun 30, 2017 | $27.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $20.47M | – |
| Q4 FY2016 | Dec 31, 2016 | $39.13M | – |
See a number that looks wrong?